Is MTLS a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Materialise (MTLS) rests on Medical is the differentiated business: Materialise makes patient-specific surgical guides and implants from CT scans, a regulated business with clinical validation and hospital relationships behind it. The bear case rests on the general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. Analysts covering it publish targets from $8.09 to $9.65 against a $8.00 price, so even the professionals disagree by 18% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Materialise is a Belgian additive manufacturing company that combines 3D printing software, a large printing service bureau, and a medical device business making patient-specific surgical guides and implants. It reports in euros through three segments (Medical, Manufacturing and Software) and has about 2,556 employees. Materialise is more diversified than a pure printer maker, with software and medical revenue alongside the service bureau, and the segments have very different economics. In the second quarter of 2026 group revenue was about EUR 70.1 million, up more than 8% year over year, with adjusted EBITDA of about EUR 9.6 million (a 13.7% margin) and net profit of about EUR 3.3 million, or EUR 0.06 per share, ahead of the roughly 0.04 consensus. Medical grew more than 12% (medical devices up 19%), Manufacturing grew nearly 7% to about EUR 23.6 million on a 40% jump in aerospace work, and Software fell 3% to about EUR 9.6 million. Management reaffirmed 2026 revenue guidance of EUR 273 to 283 million and raised adjusted EBIT guidance to EUR 12 to 14 million. The company sold its RapidFit business in April and its Eyewear business in July 2026 (keeping a 20% stake in Eyewear), held about EUR 74 million of net cash at mid-year, and has been buying back ADSs. Over the trailing twelve months revenue was about $273 million and net income about $13 million. The shares have risen about 48% year to date and 32% over one year as of October 16, 2026, and third-quarter results are due October 28, 2026.
The bull case: what would have to be true for $9.65
The most optimistic published target on MTLS is $9.65, +20.6% from the $8.00 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
Medical is the differentiated business
Materialise makes patient-specific surgical guides and implants from CT scans, a regulated business with clinical validation and hospital relationships behind it. That is harder to replicate than printing capacity and carries better economics than general service work. Medical devices revenue grew 19% in the second quarter of 2026, and the company also took a stake in Replasia, a Belgian medtech startup focused on hip preservation.
Software licensed across the industry
Its build-preparation and workflow software is used with third-party printers, including competitors' machines. That gives Materialise a position independent of whose hardware wins. About 86% of software revenue is recurring, though segment revenue fell 3% in Q2 2026 and the CO-AM Pro platform launch is the near-term product to watch.
Service bureau scale, tilting toward aerospace and defense
Operating one of the larger printing bureaus means Materialise sells parts rather than machines, which tracks production demand rather than customer capital budgets. In 2026 aerospace has been the fastest-growing piece (up 40% in Q2), helped by a partnership with Lufthansa Technik, and Materialise is also working on a defense project for the Belgian Cyber Force. The segment was still slightly loss-making at the adjusted EBITDA level in Q2, but the loss narrowed.
Portfolio clean-up and a net-cash balance sheet
Divesting RapidFit and most of Eyewear narrows the company to its core segments. With about EUR 74 million of net cash at mid-2026, positive free cash flow (about EUR 11.4 million in the first half) and an ongoing ADS buyback, Materialise has room to invest without relying on outside funding.
The bear case: what would have to be true for $8.09
The most pessimistic published target is $8.09, +1.1% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Materialise is worth if the risks below bite instead of the drivers above.
The general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. Medical revenue is regulated, so approvals and reimbursement decisions affect it directly. As a Belgian company reporting in euros, results are exposed to currency movements against the dollar. The additive industry overall has grown more slowly than forecast for a decade. Operating margins are thin (under 1% on a trailing GAAP basis), so small revenue misses swing earnings, and after a 48% year-to-date rise the shares trade near the analyst mean target of about $8.82 with only three analysts covering the stock. Leadership turnover in the medical segment (its head left in September 2026) is a further execution watch point.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MTLS already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MTLS
3 analysts cover MTLS, with an average target of $8.82 (+10.3% against $8.00) and a split of 2 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MTLS forecast and price target page.
How is MTLS valued? (as of October 2026)
Snapshot for MTLS as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$273 million
- Revenue growth (Q2 2026, YoY): ~+8%
- Net income (TTM): ~$13 million
- Gross margin: ~57%
- 2026 revenue guidance: EUR 273-283 million
- P/E (trailing / forward): ~29x / ~31x
- Market cap: ~$464 million
- Dividend: None
Materialise trades at about 1.7x trailing sales and roughly 29x trailing earnings, with about $134 million of cash against about $60 million of debt. The multiple has expanded with the share price in 2026, while consensus expects only modest earnings per share this year and next, so the valuation leans on medical and aerospace growth continuing. Reported figures are converted from euros and move with the exchange rate.
How do you decide if MTLS is a buy?
Rather than asking whether MTLS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MTLS indirectly through an index or sector ETF before adding more.
What would change your mind on MTLS
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Medical is the differentiated business stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MTLS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MTLS against your real portfolio and see your actual exposure before deciding.
Investing in Materialise with AI
Connect the broker you already use and ask Walnut's AI how MTLS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MTLS a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Medical is the differentiated business, with revenue (ttm) at ~$273 million. The bear case rests on the general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. Analysts covering it are spread from $8.09 to $9.65, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MTLS?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $8.09, +1.1% from the $8.00 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MTLS?
+
Medical is the differentiated business. Materialise makes patient-specific surgical guides and implants from CT scans, a regulated business with clinical validation and hospital relationships behind it. The most optimistic analyst target on MTLS is $9.65, +20.6% from the $8.00 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MTLS?
+
The general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. Medical revenue is regulated, so approvals and reimbursement decisions affect it directly. As a Belgian company reporting in euros, results are exposed to currency movements against the dollar. The additive industry overall has grown more slowly than forecast for a decade. Operating margins are thin (under 1% on a trailing GAAP basis), so small revenue misses swing earnings, and after a 48% year-to-date rise the shares trade near the analyst mean target of about $8.82 with only three analysts covering the stock. Leadership turnover in the medical segment (its head left in September 2026) is a further execution watch point. The most pessimistic published target is $8.09, +1.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Materialise do?
+
Materialise is a Belgian additive manufacturing company that combines 3D printing software, a large printing service bureau, and a medical device business making patient-specific s
What would have to change for MTLS to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Medical is the differentiated business) stalling in the reported numbers rather than in the narrative, the risk above (the general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Materialise do?
+
Materialise is a Belgian additive manufacturing company that combines 3D printing software, a large printing service bureau, and a medical device business making patient-specific surgical guides and implants. It reports through Medical, Manufacturing and Software segments.
Is MTLS a good stock to buy?
+
That depends on your thesis, time horizon and what you already hold, not on any single call. The case and the risks are both set out on this page. Walnut is informational and not a registered investment adviser, so treat this as research rather than a recommendation.
How did Materialise do in its latest quarter?
+
In Q2 2026 revenue rose more than 8% to about EUR 70.1 million, adjusted EBITDA rose almost 16% to about EUR 9.6 million, and net profit was about EUR 3.3 million (EUR 0.06 per share, ahead of estimates). Medical devices grew 19% and aerospace 40%, while software fell 3%. Management raised 2026 adjusted EBIT guidance to EUR 12 to 14 million. Q3 results are due October 28, 2026.
Walnut is informational, not investment advice, and gives no verdict on MTLS. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature MTLS
MTLS is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.